{"metadata": {"source": "pubchem", "title": "Gabapentin | C9H17NO2 | CID 3446 - PubChem", "description": "Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3446", "drug": "Gabapentin", "cid": 3446, "char_count": 132543, "word_count": 16838, "doc_id": "doc_28", "num_chunks": 178, "chunk_id": "28::chunk_109", "document_index": 28, "latency_s": 1.3458153000101447, "prompt_toks": 35693, "completion_toks": 69, "relevance_score": 0.8171371}, "content": "Drug: Gabapentin | cid: 3446\nSource: pubchem | Source description: Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Drug or laboratory test interactions: Gabapentin's addition to other antiepileptic drugs might lead to false positive readings of urinary protein. Thus, the sulfosalicylic acid precipitation test is recommended to assess urine protein presence accurately.\n\n12.1.11 Acute Effects\n\n12.1.12 Toxicity Data\n\nLD50: >8000 mg/kg (oral,rat) [MSDS] LD50: 8053 mg/kg (oral, mouse) [MSDS]\n\n12.1.13 Treatment\n\nGabapentin can be removed by hemodialysis. (L1712)\n\n12.1.14 Interactions\n\nWhen gabapentin is administered with morphine, patients should be observed for signs of central nervous system (CNS) depression, such as somnolence, sedation and respiratory depression\n\nNIH; DailyMed. Current Medication Information for Neurontin (Gabapentin) Capsule; Neurontin (Gabapentin) Tablet, Film-coated; Neurontin (Gabapentin) Solution (Updated: August 2016). Available from, as of October 28, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388\n\n\n                    Context: \n                    This chunk provides detailed information on gabapentin's acute effects, toxicity data, treatment options, and drug interactions, notably highlighting the risk of CNS depression when combined with morphine. It complements the overall document's comprehensive profile of gabapentin’s pharmacology, safety, and laboratory test considerations, facilitating targeted retrieval of safety and interaction data.\n                "}
{"metadata": {"source": "pubchem", "title": "Gabapentin | C9H17NO2 | CID 3446 - PubChem", "description": "Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3446", "drug": "Gabapentin", "cid": 3446, "char_count": 132543, "word_count": 16838, "doc_id": "doc_28", "num_chunks": 178, "chunk_id": "28::chunk_91", "document_index": 28, "latency_s": 1.4398246000055224, "prompt_toks": 35555, "completion_toks": 93, "relevance_score": 0.53567535}, "content": "Drug: Gabapentin | cid: 3446\nSource: pubchem | Source description: Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Gabapentin toxicity is seen in those with chronic kidney disease or undergoing hemodialysis, showing symptoms like tremors, altered mental states, and respiratory depression requiring intubation. Reports of rhabdomyolysis due to gabapentin have been described. No antidote for gabapentin poisoning currently exists. Gabapentin can be removed through dialysis. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup recommends refraining from utilizing extracorporeal treatments (ECTR) and standard care for gabapentin poisoning in patients with normal kidney function. However, if reduced kidney function and coma necessitating mechanical ventilation are evident, the EXTRIP suggests incorporating ECTR and standard care.\n\n\n                    Context: \n                    This excerpt discusses the toxic effects and management of gabapentin overdose, highlighting symptoms such as tremors, altered mental states, and respiratory depression in patients with kidney impairment. It also details the current lack of a specific antidote, the role of dialysis in removal, and guidelines from the EXTRIP workgroup on when extracorporeal treatments are appropriate, emphasizing its relevance to the broader pharmacology, safety, and toxicity sections of the comprehensive drug profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Gabapentin | C9H17NO2 | CID 3446 - PubChem", "description": "Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3446", "drug": "Gabapentin", "cid": 3446, "char_count": 132543, "word_count": 16838, "doc_id": "doc_28", "num_chunks": 178, "chunk_id": "28::chunk_117", "document_index": 28, "latency_s": 1.2767415999987861, "prompt_toks": 35652, "completion_toks": 88, "relevance_score": 0.24364243}, "content": "Drug: Gabapentin | cid: 3446\nSource: pubchem | Source description: Gabapentin | C9H17NO2 | CID 3446 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    For more Antidote and Emergency Treatment (Complete) data for GABAPENTIN (8 total), please visit the HSDB record page.\n\n12.1.16 Human Toxicity Excerpts\n\n/SIGNS AND SYMPTOMS/ Acute oral overdoses of Neurontin up to 49 grams have been reported. In these cases, double vision, slurred speech, drowsiness, lethargy, and diarrhea were observed. All patients recovered with supportive care. Coma, resolving with dialysis, has been reported in patients with chronic renal failure who were treated with Neurontin.\n\nNIH; DailyMed. Current Medication Information for Neurontin (Gabapentin) Capsule; Neurontin (Gabapentin) Tablet, Film-coated; Neurontin (Gabapentin) Solution (Updated: August 2016). Available from, as of October 28, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388\n\n\n                    Context: \n                    This excerpt provides detailed information on the human toxicity and overdose symptoms of gabapentin (Neurontin), including clinical signs such as double vision, slurred speech, and support care outcomes. It references the authoritative HSDB record for comprehensive antidote and emergency treatment data, making it highly relevant for safety, toxicity, and emergency response sections within the full chemical profile. The source citation and link ensure reliable access for further detailed emergency information.\n                "}
